Brokerages predict that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will report earnings per share (EPS) of ($0.25) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.21). Adaptimmune Therapeutics posted earnings of ($0.22) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 13.6%. The company is expected to issue its next quarterly earnings results on Monday, March 12th.
On average, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.69). For the next year, analysts anticipate that the business will report earnings of ($0.75) per share, with EPS estimates ranging from ($1.13) to ($0.39). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Adaptimmune Therapeutics.
Several research analysts have issued reports on ADAP shares. BidaskClub lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. ValuEngine lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. SunTrust Banks restated a “buy” rating and issued a $10.00 price target on shares of Adaptimmune Therapeutics in a research report on Friday, November 10th. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, TheStreet upgraded shares of Adaptimmune Therapeutics from a “d” rating to a “c” rating in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $11.58.
Adaptimmune Therapeutics (ADAP) traded up $0.11 during trading on Friday, reaching $8.62. 301,201 shares of the company’s stock traded hands, compared to its average volume of 613,108. The firm has a market capitalization of $797.28, a price-to-earnings ratio of -11.34 and a beta of 1.74. Adaptimmune Therapeutics has a 12-month low of $3.88 and a 12-month high of $9.70.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.